GNFTF - Biotech Analysis Central Pharma News: Pfizer's Setback Genfit's Advance Sage's Postponement
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
Pfizer Suffers Setback With Partner Merck KGaA On PD-L1 Drug Bavencio
News: Recently, Pfizer (PFE) and Merck KGaA (MKKGY) announced that they had failed a phase 3 study using bavencio to treat patients with platinum-resistant or refractory ovarian cancer. This phase 3 study was known as JAVELIN and recruited 200 patients in total. Patients were treated with either bavencio alone as a monotherapy, bavencio in combination with chemotherapy (pegylated